[A21-48] Rilpivirine (HIV infection) - Benefit assessment according to §35a Social Code Book V
Last updated 02.08.2021
Project no.:
A21-48
Commission:
Commission awarded on 03.05.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Immune system and infections
Adults with HIV-1 infection who are virologically suppressed on a stable antiretroviral regimen, without resistance to, and no virological failure with non-nucleoside reverse transcriptase inhibitors (NNRTIs) or integrase inhibitors (INIs)
Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A12-04 | Rilpivirine - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A15-55 | Rilpivirine (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V | Commission completed |